Abstract |
Fundamental and clinical studies on imipenem/cilastatin sodium ( MK-0787/ MK-0791), a new carbapenem antibiotic, were performed and the following results were obtained. Concentrations of MK-0787 and MK-0791 in serum, internal genital organs and retroperitoneal fluid were determined after a 30 minutes drip infusion of 500 mg/500 mg dose. Venous serum levels of MK-0787 and MK-0791 were 47.3 to 67.5 micrograms/ml and 44.2 to 61.4 micrograms/ml, respectively, at the end of the administration. Sufficient transfer of MK-0787 and MK-0791 to internal genital organs and retroperitoneal fluid was demonstrated. In clinical trials, MK-0787/ MK-0791 was given to 18 cases with obstetrical and gynecological infections, such as endometritis, puerperal fever, pelvic peritonitis, parametritis and lymphocystitis. The clinical efficacy was evaluated as excellent in 1 case, good in 14 and poor in 3. The efficacy rate was 83.3%. In a bacteriological study, 43 strains were isolated from 16 cases and the eradication rate was 61.1%. No side effects were observed in any of the cases. In laboratory findings, a transient elevation of GOT, GPT was noted in 1 case. From the above results, it was concluded that MK-0787/ MK-0791 was useful drug for infections in the field of obstetrics and gynecology.
|
Authors | T Yamamoto, J Yasuda, M Tomioka, M Kanao, H Okada |
Journal | The Japanese journal of antibiotics
(Jpn J Antibiot)
Vol. 39
Issue 6
Pg. 1583-94
(Jun 1986)
ISSN: 0368-2781 [Print] Japan |
PMID | 3463798
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Cyclopropanes
- Drug Combinations
- Thienamycins
- Cilastatin
- Imipenem
- Dipeptidases
|
Topics |
- Adult
- Aged
- Bacterial Infections
(drug therapy)
- Cilastatin
- Cyclopropanes
(administration & dosage, metabolism)
- Dipeptidases
(antagonists & inhibitors)
- Drug Combinations
- Drug Evaluation
- Female
- Genital Diseases, Female
(drug therapy)
- Genitalia, Female
(metabolism)
- Humans
- Imipenem
- Infusions, Intravenous
- Middle Aged
- Thienamycins
(administration & dosage, metabolism)
|